About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The VHIR Infectious Diseases research group is made up of medical professionals, with healthcare and clinical or basic translational research activities; of Biomedicine dedicated to basic research; and Nursing, with activities to support clinical research.
The group's lines of research are mainly focused on four areas:
Infections related to immunosuppression. Includes infectious diseases related to immunocompromised patients, solid organ or hematopoietic stem cell transplant recipients and recipients of biological therapies.
Sexually transmitted diseases, including HIV infection and other highly prevalent infections in our country (syphilis, gonorrhea, lymphogranuloma venere or infections caused by the human papillomavirus).
Infections related to health care, with special emphasis on those difficult to treat (cardiovascular infections or infections related to prosthetic materials) or caused by multi-resistant pathogens (MDRO) or affecting vulnerable populations.
Global Health and Tropical Diseases with special emphasis on prevalent diseases in our environment that affect the immigrant or displaced population.
Development of a new gene therapy strategy based on high-capacity adenoviral vectors, in collaboration with the Gene and Cell Therapy group at VHIR, led by Dr. Jordi Barquinero and Dr. María Pallarès-Masmitjà.
IP: David Gómez Andrés
The application of advanced magnetic resonance imaging (MRI) techniques enables an objective and quantitative characterization of the progression of various neurological diseases. This research focuses on developing imaging biomarkers to identify radiological patterns. For neuromuscular diseases, the aim is to identify specific patterns of fat replacement and muscle inflammation, as well as to correlate these changes with motor function and other clinical parameters. For patients with movement disorders, specific imaging patterns will be studied to establish efficacy biomarkers for deep brain stimulation. This will contribute to better patient stratification and evaluation of responses to different experimental treatments.
IP: Belen Perez Dueñas, David Gómez Andrés
IP: Jordi Bove Badell Collaborators: Oscar Len Abad, Jordi Mollet Sánchez, Xavier Serres Créixams, Oriol de Fabregues-Boixar Nebot, Maria Piñana Moro Funding agency: Instituto de Salud Carlos III Funding: 221250 Reference: PI24/01820 Duration: 01/01/2025 - 31/12/2027
IP: Meritxell Genesca Ferrer Collaborators: Patricia Álvarez López, Aleix Benítez Martínez Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 231250 Reference: PID2023-149204OB-I00 Duration: 01/09/2024 - 31/12/2027
IP: Esperanza Esteban Serna Collaborators: - Funding agency: EUROPEAN COMMISSION Funding: 528074.96 Reference: CHANCE_DIREITOS-HUMANOS-&-DEMOCRACIA2023 Duration: 01/05/2024 - 30/04/2028
IP: Adria Curran Fàbregas Collaborators: Anna Sala Cunill, Vicenç Falcó Ferrer, Yolima Cossio Gil, Ignasi Cardona Pascual, Paula Suanzes Diez, Jordi Navarro Mercadé, Joaquin Burgos Cibrian, OPVIH (Optimización del proceso VIH): Definición del mapa del recorrido de la persona VIH y oportunidades para su optimización m, Maria Belén Gutiérrez Iglesias, Silvina Andrea Magnani Funding agency: Laboratorio ViiV Healthcare Funding: 55000 Reference: VIIV/BECAS/2023/CURRAN Duration: 15/01/2024 - 14/01/2026
The grants support projects led by Drs. María José Buzón, María Buti, Elena Élez, and Maria Vieito.
AIDAY 2026 showcased the artificial intelligence initiatives, infrastructures and projects already being developed across the Campus.
All patients showed a favorable clinical course and responded well to antibiotic treatment, without complications.
